Why vaccines may weaken with age: new study investigates
NCT ID NCT06128915
First seen Mar 05, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This study explores why older adults often have weaker responses to the pneumococcal vaccine, which protects against pneumonia. Researchers will compare immune cells called neutrophils in 60 healthy young (21-40) and older (65+) adults before and after vaccination. The goal is to understand how aging affects the body's ability to fight off pneumococcal bacteria after vaccination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGING are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University at Buffalo
RECRUITINGBuffalo, New York, 14203, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pneumococcal vaccine (Prevnar-13, covering 20 serotypes)
What this could lead to
If successful, this could explain why older adults respond less to vaccines and point toward ways to improve vaccine effectiveness in the elderly.
What could go wrong
This is a small, early-stage observational study (60 participants) that measures immune cell activity, not clinical outcomes. It may not lead to any direct treatment or vaccine change.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.